Archive

Clinical trials vs real life

Dr Filip Baert (Roeselare, Belgium) gives a summary of his session on trial endpoints vs therapeutic objectives. he also discusses the role of ECCO in improving the data generated in… read more.

Predicting disease years before diagnosis

Predicting disease years before diagnosis is a passion for Professor Jean-Frederic Colombel (Icahn School of Medicine at Mount Sinai, NY, USA). Here he discusses 2 studies presented at… read more.

ECCO 2016: Professor Stefan Schreiber (Kiel, Germany) discusses some of the issues in managing Crohn's disease.

In it for the long haul – managing the complexity of Crohn’s disease by Maria Dalby Michael Kamm (Melbourne, Australia), Remo Panaccione (Alberta, Canada) and Stefan Schreiber (Kiel,… read more.

ECCO 2016: Professor Stefan Schreiber (Kiel, Germany) discusses some of the issues in managing Crohn’s disease.

In it for the long haul – managing the complexity of Crohn’s disease by Maria Dalby Michael Kamm (Melbourne, Australia), Remo Panaccione (Alberta, Canada) and Stefan Schreiber (Kiel,… read more.

ECCO 2016: Marian O’Connor (Harrow, UK) and Helen Terry (CCUK) discuss the importance of the IBD nurse, how the role has changed, how the UK had led the way and what the future holds for IBD nurses.

The future is now – importance of the IBD nurse in patient care. by Maria Dalby Marian O’Connor (St Mark’s Hospital, London, UK ), Silvio Danese (Milan, Italy)… read more.

ECCO 2016: Dr Ailsa Hart (St Mark’s Hospital IBD Unit, Harrow, UK) discusses the issues raised at this year’s ECCO around cost effectiveness in IBD.

ECCO 2016: Helen Terry (CCUK Director of Policy, Research and Public Affairs, UK) discusses the impact on IBD care of involving patients in patient panels.

ECCO 2016: Specialists gathered to discuss new data and current issues and solutions in IBD. Professor David Rubin (Chicago, USA), ECCO President Professor Séverine Vermeire (Leuven, Belgium), Professor Stefan Schreiber (Kiel, Germany) and Dr Peter Irving (London, UK) took time out to discuss with IBD.Update what they are excited about what’s coming up in the near future for patients with IBD.

ECCO 2016: Mechanisms by which inflammation resolves

Silvio Danese, Humanitas Clinical and Research Hospital, Milan, Italy. Article by Maria Dalby – The current paradigm for managing inflammatory conditions is to suppress the inflammatory response by… read more.

ECCO 2016: IOIBD: Disease severity definition in IBD. Professor Laurent Peyrin-Biroulet (Nancy University Hospital, France) discusses a new disease severity score initiated by the IOIBD

ECCO 2016: Dr Charlie Lees (Edinburgh, UK), Dr Ailsa Hart and Marian O’Connor (Harrow, UK), Dr James Lindsay (London, UK) and Dr Peter Irving (London, UK) discuss the new therapeutic landscape in IBD since changes to guidance by NICE and SMC over the last year

New drugs in IBD – by Maria Dalby Tofacitinib Two randomised placebo-controlled phase 3 studies (OCTAVE Induction 1 and 2) show that tofacitinib, an oral small-molecule Janus kinase… read more.

ECCO 2016: Dr Charlie Lees (Edinburgh, UK) discusses in the video and article below the factors influencing the decision to stop treatment and discussed whether it may be possible to predict relapse using currently available methods

Stopping drugs – by Maria Dalby Charles Lees (Edinburgh, UK) Medication constitutes a large part of the IBD exposome, and stopping drug treatment should be a therapeutic goal… read more.